Subscribe
Be the first with the news that moves the market- Aequus Pharmaceuticals (TSXV:AQS) has achieved an important regulatory step towards the Canadian launch of its Evolve dry eye product line
- The product manufacturer, Medicom Healthcare, has met the standards of Canada’s Medical Device Single Audit Program
- Aequus also does not anticipate any disruptions to the products’ supply chain
- The company expects to file for Health Canada approval between June and the third quarter
- Aequus Pharmaceuticals (AQS) remains unchanged, trading for 10 cents per share
Aequus Pharmaceuticals (TSXV:AQS) has achieved an important regulatory step towards the Canadian launch of its Evolve dry eye product line.
The UK product manufacturer, Medicom Healthcare, has successfully met the standards of MDSAP, the Canadian Medical Device Single Audit Program. The MDSAP sets the standard for all medical device manufacturers who distribute in Canada.
In its press release today, Aequus expressed how pleased it was to have achieved this important milestone.
While the auditing bodies prepare the formal MDSAP certification, the company’s plans for the Canadian launch are well underway. Aequus expects that it will receive the formal certificate between June and 2020’s third quarter.
At that point, the company will file for Health Canada’s approval of the dry eye product line.
Thankfully, Aequus has reported that Medicom Healthcare is continuing to manufacture and distribute products to 35 countries. As a result, the company does not anticipate any disruptions to the supply chain for Evolve products, despite COVID-19’s impact.
Aequus is integrating new flexibility into its strategic business model, in response to the circumstances surrounding the pandemic. Aequus’ Director and COO, Anne Stevens, commented on the company’s efforts to adapt in a COVID-19 environment.
“During this time, Aequus is working diligently to prepare for a new normal, by crafting innovative models that integrate existing retail structures, with more wide-reaching virtual channels.
“These models will virtually support Canadian optometry clinic retailers who have been forced to close, while simultaneously expanding the availability of Evolve products to patients at launch,” she said.
Aequus Pharmaceuticals (AQS) remains unchanged, trading for 10 cents per share, as of 12:49pm EST.
